SDIX will sell its life science assets to OriGene Technologies for $16 million. The deal is expected to be finalized this quarter. SDIX's knowledge in antibody development and production "will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies," OriGene Chairman and CEO Wei-Wu He said.

Related Summaries